Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
16 participants
INTERVENTIONAL
2019-03-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacological Activation of HMN for OSA
NCT03640052
Mechanisms of Upper Airway Obstruction
NCT04322097
Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea
NCT03892772
The Effects of Nasal Airflow on Upper Airway Dilator Muscles During Sleep
NCT03506178
DAW1033D in Obstructive Sleep Apnea
NCT03383887
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo capsule before bedtime
Placebo oral capsule
Placebo capsule before bedtime
LTM1201AZ
LTM1201AZ capsule before bedtime
LTM1201AZ
LTM1201AZ oral capsule before sleep
LTM1201AT
LTM1201AT capsule before bedtime
LTM1201AT
LTM1201AT oral capsule before sleep
LTM1201AG
LTM1201AG capsule before bedtime
LTM1201AG
LTM1201AG oral capsule before sleep
LTM1201AD
LTM1201AD capsule before bedtime
LTM1201AD
LTM1201AD oral capsule before sleep
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo oral capsule
Placebo capsule before bedtime
LTM1201AZ
LTM1201AZ oral capsule before sleep
LTM1201AT
LTM1201AT oral capsule before sleep
LTM1201AG
LTM1201AG oral capsule before sleep
LTM1201AD
LTM1201AD oral capsule before sleep
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any medication known to influence breathing, sleep/arousal, or muscle physiology.
* Claustrophobia.
* Inability to sleep supine.
* Allergy to any of the medications tested in the protocol.
* History of kidney stones, hypercalcemia, primary hyperparathyroidism, sarcoidosis, hypervitaminosis D.
* Individuals with underlying cardiac disease, such as arrhythmias.
* Individuals taking psychiatric medications, such as an MAO-I, SSRI or SNRI, or any of the studied medications for medical care.
* For women: Pregnancy.
* Pulmonary hypertension
* Severe OSA with a mean SaO2 lower than 88%
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brigham and Women's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Scott Aaron Sands
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018p001201aim2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.